Growth Metrics

Quest Diagnostics (DGX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Quest Diagnostics (DGX) over the last 17 years, with Q3 2025 value amounting to $16.2 billion.

  • Quest Diagnostics' Liabilities and Shareholders Equity rose 63.37% to $16.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $64.1 billion, marking a year-over-year increase of 1063.64%. This contributed to the annual value of $16.2 billion for FY2024, which is 1519.75% up from last year.
  • As of Q3 2025, Quest Diagnostics' Liabilities and Shareholders Equity stood at $16.2 billion, which was up 63.37% from $16.0 billion recorded in Q2 2025.
  • Quest Diagnostics' Liabilities and Shareholders Equity's 5-year high stood at $16.2 billion during Q3 2025, with a 5-year trough of $12.8 billion in Q1 2023.
  • Over the past 5 years, Quest Diagnostics' median Liabilities and Shareholders Equity value was $13.6 billion (recorded in 2021), while the average stood at $14.1 billion.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 568.66% in 2022, then soared by 1938.14% in 2024.
  • Quarter analysis of 5 years shows Quest Diagnostics' Liabilities and Shareholders Equity stood at $13.6 billion in 2021, then decreased by 5.69% to $12.8 billion in 2022, then grew by 9.23% to $14.0 billion in 2023, then grew by 15.2% to $16.2 billion in 2024, then rose by 0.27% to $16.2 billion in 2025.
  • Its last three reported values are $16.2 billion in Q3 2025, $16.0 billion for Q2 2025, and $15.8 billion during Q1 2025.